EXPERIENCE
Medical Doctor, Regeneron VP and Head Global Franchise Oncology MA
Celgene (BMS) Vice President, GMA Early Assets
University of Miami Sylvester Professor and Assistant Director of the Sylvester Comprehensive Cancer Center
University of Calgary Professor of Oncology, Medicine and Pharmacology
EDUCATION
Fraie Universität Berlin
RWTH Aachen University
University of Toronto
Princess Margarete Hospital – Toronto
Stefan Glück, MD, PhD
SR. VICE PRESIDENT, MEDICAL AFFAIRS
Stefan Glück, M.D., PhD, is a medical oncologist specializing in breast, ovarian, and bladder cancers, as well as immunology and hematology. He has led early-stage development studies of solid tumors and immuno-oncology. He has deep expertise in clinical trials, acting as the PI in several dozen.
Dr. Glück has authored/co-authored more than 250 articles, presented more than 350 papers at national and international meetings, and written/co-written multiple book chapters. He is a reviewer of several journals, including the Journal of Clinical Oncology, European Journal of Cancer, Lancet Oncology, Lancet, Breast Cancer Research, The Oncologist, The Breast Journal, and Clinical Breast Cancer.
Dr. Glück was presented the America’s Top Oncologists 2008 award from Consumers’ Research Council of America; he also received the Best Doctors in America honor in since 2006, and has annually earned that prestige every year, including in 2014; this award was warranted after less than 3 years of working in the United States.
Featured In
Photochem Photobiol The selective uptake of benzoporphyrin derivative mono-acid ring A results in differential cell kill of multiple myeloma cells in vitro. June 5, 1996
Breast Cancer Research and Treatment A cost-benefit analysis of bevacizumab in combination with paclitaxel in the first-line treatment of patients with metastatic breast cancer Apr 1, 2012
Biomarkers in Cancers/Libertas Academia Molecular Profiling for Breast Cancer: A Comprehensive Review Oct 29, 2013